We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NEWS IN MULTIPLE SCLEROSIS TREATMENT.
- Authors
AVRAM, M. G.; PEREANU, M.
- Abstract
The therapeutic arsenal in Multiple Sclerosis (MS) has developed after the 90's by using betainterferon, glatiramer acetate, and then natalizumab. Currently, five oral therapies are in phase III studies or have recently been approved for the treatment of relapsing-remitting MS: cladribine (approved in Russia and Australia), fingolimod (approved in the US and Russia), BG-12 (phase III), laquinimod (phase III) and teriflunomide (phase III). The new monoclonal antibodies shall innaugurate the second generation after natalizumab.
- Subjects
AUSTRALIA; RUSSIA; UNITED States; MULTIPLE sclerosis treatment; ARSENALS; IMMUNOGLOBULINS
- Publication
Acta Medica Transilvanica, 2011, Vol 16, Issue 1, p272
- ISSN
1453-1968
- Publication type
Article